keyword
MENU ▼
Read by QxMD icon Read
search

New diabetes trials

keyword
https://www.readbyqxmd.com/read/28230330/comparing-six-antihypertensive-medication-classes-for-preventing-new-onset-diabetes-mellitus-among-hypertensive-patients-a-network-meta-analysis
#1
Yang Yang, Huilan Xu
Hypertensive patients usually have a higher risk of new-onset diabetes mellitus (NOD) which may trigger cardiovascular diseases. In this study, the effectiveness of six antihypertensive agents with respect to NOD prevention in hypertensive patients was assessed. A network meta-analysis was conducted to compare the efficacy of specific drug classes. PubMed and Embase databases were searched for relevant articles. Results of the pairwised meta-analysis were illustrated by odd ratios (OR) and a corresponding 95% confidence interval (CI)...
February 23, 2017: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/28222165/stress-increases-the-risk-of-type-2-diabetes-onset-in-women-a-12-year-longitudinal-study-using-causal-modelling
#2
Melissa L Harris, Christopher Oldmeadow, Alexis Hure, Judy Luu, Deborah Loxton, John Attia
BACKGROUND: Type 2 diabetes is associated with significant morbidity and mortality. Modifiable risk factors have been found to contribute up to 60% of type 2 diabetes risk. However, type 2 diabetes continues to rise despite implementation of interventions based on traditional risk factors. There is a clear need to identify additional risk factors for chronic disease prevention. The aim of this study was to examine the relationship between perceived stress and type 2 diabetes onset, and partition the estimates into direct and indirect effects...
2017: PloS One
https://www.readbyqxmd.com/read/28205039/a-pooled-analysis-of-clinical-pharmacology-trials-investigating-the-pharmacokinetic-and-pharmacodynamic-characteristics-of-fast-acting-insulin-aspart-in-adults-with-type-1-diabetes
#3
Tim Heise, Thomas R Pieber, Thomas Danne, Lars Erichsen, Hanne Haahr
BACKGROUND: Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation aiming to mimic the fast endogenous prandial insulin release more closely than currently available insulin products. In a post hoc analysis of pooled data from six clinical pharmacology trials, the pharmacological characteristics of faster aspart and IAsp were compared. METHODS: The analysis included 218 adult subjects with type 1 diabetes from six randomised, double-blind, crossover trials in the faster aspart clinical development programme...
February 15, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28198767/anti-gal-and-anti-neu5gc-responses-in-nonimmunosuppressed-patients-following-treatment-with-rabbit-anti-thymocyte-polyclonal-iggs
#4
Apolline Salama, Gwénaëlle Evanno, Noha Lim, Juliette Rousse, Ludmilla Le Berre, Arnaud Nicot, Sophie Brouard, Kristina M Harris, Mario R Ehlers, Stephen E Gitelman, Jean-Paul Soulillou
BACKGROUND: Polyclonal anti-human thymocyte rabbit IgGs (anti-thymocyte globulin, ATG) are popular immunosuppressive drugs used to prevent or treat organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases. However, animal-derived glycoproteins are also strongly immunogenic and rabbit ATG induces serum sickness disease in almost all patients without additional immunosuppressive drugs, as seen in the START trial of ATG therapy in new-onset type 1 diabetes...
February 14, 2017: Transplantation
https://www.readbyqxmd.com/read/28197977/interpreting-cardiovascular-endpoints-in-trials-of-antihyperglycemic-drugs
#5
REVIEW
Himika Chawla, Nikhil Tandon
In view of the significant cardiovascular (CV) morbidity and mortality in patients with type 2 diabetes mellitus, and concerns raised about the CV safety of some glucose-lowering drugs, the US Food and Drug Administration (FDA) issued guidance for the industry in 2008 to demonstrate CV safety for the approval of all new antihyperglycemic drugs. Seven randomized controlled trials involving around 60,000 participants have been completed so far and have demonstrated the CV safety of dipeptidyl peptidase 4 inhibitors (saxagliptin, alogliptin and sitagliptin), glucagon-like peptide-1 receptor agonists (lixisenatide, liraglutide and semaglutide) and a sodium-glucose co-transporter 2 inhibitor (empagliflozin) in patients with type 2 diabetes...
February 14, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/28176222/saxagliptin-dapagliflozin-a-review-in-type-2-diabetes-mellitus
#6
Karly P Garnock-Jones
Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern(®)) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin + dapagliflozin. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of saxagliptin/dapagliflozin in this indication...
February 7, 2017: Drugs
https://www.readbyqxmd.com/read/28166816/the-achru-cpp-versus-usual-care-for-older-adults-with-type-2-diabetes-and-multiple-chronic-conditions-and-their-family-caregivers-study-protocol-for-a-randomized-controlled-trial
#7
Maureen Markle-Reid, Jenny Ploeg, Kimberly D Fraser, Kathryn Ann Fisher, Noori Akhtar-Danesh, Amy Bartholomew, Amiram Gafni, Andrea Gruneir, Sandra P Hirst, Sharon Kaasalainen, Caralyn Kelly Stradiotto, John Miklavcic, Carlos Rojas-Fernandez, Cheryl A Sadowski, Lehana Thabane, Jean A C Triscott, Ross Upshur
BACKGROUND: Many community-based self-management programs have been developed for older adults with type-2 diabetes mellitus (T2DM), bolstered by evidence from randomized controlled trials (RCTs) that T2DM can be prevented and managed through lifestyle modifications. However, the evidence for their effectiveness is contradictory and weakened by reliance on single-group designs and/or small samples. Additionally, older adults with multiple chronic conditions (MCC) are often excluded because of recruiting and retention challenges...
February 6, 2017: Trials
https://www.readbyqxmd.com/read/28165180/faster-acting-insulin-aspart-provides-faster-onset-and-greater-early-exposure-vs-insulin-aspart-in-children-and-adolescents-with-type-1-diabetes-mellitus
#8
Maryam Fath, Thomas Danne, Torben Biester, Lars Erichsen, Olga Kordonouri, Hanne Haahr
BACKGROUND: Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with additional excipients (L-arginine and niacinamide). In adults, faster aspart provides faster onset and greater early exposure and action vs IAsp. AIM: This randomized, double-blind, 2-period crossover trial investigated the pharmacological properties of faster aspart vs IAsp in 12 children (6-11 years), 13 adolescents (12-17 years), and 15 adults (18-64 years) with type 1 diabetes mellitus...
February 6, 2017: Pediatric Diabetes
https://www.readbyqxmd.com/read/28163748/weight-loss-technology-for-people-with-treated-type-2-diabetes-a-randomized-controlled-trial
#9
Kuat Oshakbayev, Bibazhar Dukenbayeva, Gulnar Togizbayeva, Aigul Durmanova, Meruyert Gazaliyeva, Abdul Sabir, Aliya Issa, Alisher Idrisov
BACKGROUND: The prevalence of type 2 diabetes is increasing in worldwide despite the development of new treatment methods. Aim of the study was to evaluate a weight loss method on body composition, glycemic, lipid and hormone profiles, blood pressure and reactive oxygen species in people with treated type 2 diabetes. METHODS: A 24-week open, prospective, randomized, controlled clinical trial including 272 adult patients with treated type 2 diabetes was performed...
2017: Nutrition & Metabolism
https://www.readbyqxmd.com/read/28159561/effects-of-statin-therapy-on-weight-loss-and-diabetes-in-bariatric-patients
#10
Beth A Taylor, Janet Ng, Andrea Stone, Paul D Thompson, Pavlos K Papasavas, Darren S Tishler
BACKGROUND: Bariatric surgeries are considered effective treatments for weight loss and improved diabetes control. Statins increase diabetes onset in prospective clinical trials and many bariatric patients with metabolic disease are concurrently on statins. OBJECTIVES: We retrospectively examined the relationship of statin therapy to weight loss, diabetes mellitus onset and remission, and metabolic outcomes after bariatric surgery. SETTING: Hospital...
November 23, 2016: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/28155189/diabetes-secondary-to-treatment-with-statins
#11
REVIEW
Markku Laakso, Johanna Kuusisto
PURPOSE OF REVIEW: This review summarizes the recent population-based studies, clinical trials, clinical metabolic studies, and genetic studies reporting the effects of statin therapy on the risk of diabetes. Recent studies aiming to explain the mechanisms how statin treatment affects insulin sensitivity and insulin secretion are also reviewed. RECENT FINDINGS: Statin therapy increases the risk of diabetes by 9%-12% in the two meta-analyses of statin trials and by 18%-99% in five population-based studies...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28153000/effectiveness-of-the-cardiac-diabetes-transcare-program-protocol-for-a-randomised-controlled-trial
#12
Chiung-Jung Jo Wu, John J Atherton, Richard J MacIsaac, Mary Courtney, Anne M Chang, David R Thompson, Karam Kostner, Andrew I MacIsaac, Michael d'Emden, Nick Graves, Steven M McPhail
BACKGROUND: This paper presents a protocol for a randomised controlled trial of the Cardiac-Diabetes Transcare program which is a transitional care, multi-modal self-management program for patients with acute coronary syndrome comorbid with type 2 diabetes. Prior research has indicated people hospitalised with dual cardiac and diabetes diagnoses are at an elevated risk of hospital readmissions, morbidity and mortality. The primary aim of this study is to evaluate the effectiveness (and cost-effectiveness) of a Cardiac-Diabetes Transcare intervention program on 6-month readmission rate in comparison to usual care...
February 2, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28151518/-type-2-diabetes-treatment-and-cardiovascular-risk-what-can-we-learn-from-trials
#13
Agostino Consoli, Fabrizio Febo
Diabetes treatment should include drugs with absolutely no adverse effects toward cardiovascular risk. Indeed, it would be advisable to use drugs with intrinsic protective effect against the risk of cardiovascular events. Intervention trials aiming at demonstrating a protective cardiovascular effect of very tight glucose control have produced controversial results. It is commonly perceived, however, that early intervention with safe treatment strategies is likely to be beneficial. In regard to safety, in the attempt to firmly establish cardiovascular safety of new drugs for diabetes, Government Authorities have mandated that cardiovascular safety trials need to be performed for all new drugs registered for diabetes treatment...
December 2016: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28150516/efficacy-and-safety-of-fixed-ratio-combination-of-insulin-degludec-and-liraglutide-ideglira-for-the-treatment-of-type-2-diabetes
#14
Louise Vedtofte, Filip K Knop, Tina Vilsbøll
Type 2 diabetes (T2D) is a progressive disease with increasing prevalence in most countries. The majority of patients with T2D have inadequate glycaemic control, which increases the risk of diabetic complications later in life. New therapies with improved safety profiles are required to tackle the progressive nature of T2D. Areas covered: The efficacy and safety profile of IDegLira - a once-daily, fixed-ratio combination of insulin degludec and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), for the treatment of T2D - has been extensively evaluated...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28148253/cardiovascular-safety-of-non-insulin-pharmacotherapy-for-type-2-diabetes
#15
REVIEW
James Xu, Rohan Rajaratnam
Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily translate to cardiovascular safety. Over the past few years, there has been a number of trials evaluating the cardiovascular effects of anti-diabetic drugs. In this review, we seek to examine the cardiovascular safety of these agents in major published trials. Metformin has with-stood the test of time and remains the initial drug of choice...
February 2, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28144148/advances-in-the-management-of-cardiovascular-risk-for-patients-with-type-2-diabetes-perspectives-from-the-academy-for-cardiovascular-risk-outcomes-and-safety-studies-in-type-2-diabetes
#16
Guntram Schernthaner, Sarah Jarvis, Chaim Lotan, Martin Prázný, Christoph Wanner, Thomas C Wascher
Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28138788/young-patients-with-type-1-diabetes-poorly-controlled-and-poorly-compliant-with-self-monitoring-of-blood-glucose-can-technology-help-results-of-the-i-newtrend-randomized-clinical-trial
#17
Paolo Di Bartolo, Antonio Nicolucci, Valentino Cherubini, Diario Iafusco, Marco Scardapane, Maria Chiara Rossi
AIMS: To compare iBGStar™ + DMApp (experimental meter + telemedicine system) (iBGStar) with a traditional glucose meter (Control) in type 1 diabetes adolescents/young adults. METHODS: i-NewTrend was a multicenter, open-label, randomized trial involving subjects aged 14-24 years, on basal-bolus insulin, HbA1c ≥ 8.0%, and poorly compliant with SMBG (i.e., <30% of the recommended frequency). Primary end points were change in HbA1c and achievement of compliance with SMBG (≥30% of the recommended frequency) after 6 months...
January 30, 2017: Acta Diabetologica
https://www.readbyqxmd.com/read/28137255/the-norwegian-dietary-guidelines-and-colorectal-cancer-survival-crc-nordiet-study-a-food-based-multicentre-randomized-controlled-trial
#18
Hege Berg Henriksen, Hanna Ræder, Siv Kjølsrud Bøhn, Ingvild Paur, Ane Sørlie Kværner, Siv Åshild Billington, Morten Tandberg Eriksen, Gro Wiedsvang, Iris Erlund, Arne Færden, Marit Bragelien Veierød, Manuela Zucknick, Sigbjørn Smeland, Rune Blomhoff
BACKGROUND: Colorectal cancer survivors are not only at risk for recurrent disease but also at increased risk of comorbidities such as other cancers, cardiovascular disease, diabetes, hypertension and functional decline. In this trial, we aim at investigating whether a diet in accordance with the Norwegian food-based dietary guidelines and focusing at dampening inflammation and oxidative stress will improve long-term disease outcomes and survival in colorectal cancer patients. METHODS/DESIGN: This paper presents the study protocol of the Norwegian Dietary Guidelines and Colorectal Cancer Survival study...
January 30, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28132853/research-opportunities-and-challenges-in-the-era-of-healthy-living-medicine-unlocking-the-potential
#19
REVIEW
Shane A Phillips, Sharon Martino, Ross Arena
Non-communicable diseases, such as cardiovascular disease (CVD), obesity, cancer, pulmonary disease, and diabetes are a very high global health concern. The health costs of risk factors for CVD, such as hypertension (HTN), is mounting and are unrelenting. As an example, it is estimated that direct and indirect costs due to HTN amounted to $46.4 billion in 2011 and projections of six-fold increases by 2030; the importance of low-cost nonpharmacological interventions involving collaborative teams of health care professionals is at a critical junction...
January 26, 2017: Progress in Cardiovascular Diseases
https://www.readbyqxmd.com/read/28132685/comparison-of-frequency-of-ischemic-cardiovascular-events-in-patients-with-aortic-stenosis-with-versus-without-asymmetric-septal-hypertrophy-from-the-seas-trial
#20
Eigir Einarsen, Dana Cramariuc, Mai T Lønnebakken, Kurt Boman, Christa Gohlke-Bärwolf, John B Chambers, Eva Gerdts
Asymmetric interventricular septum hypertrophy (ASH) has been associated with increased perioperative morbidity and mortality in patients with severe, symptomatic aortic valve stenosis (AS). Less is known about the prognostic impact of ASH during progression of AS. Clinical, echocardiographic, and outcome data from 1,691 patients with initially asymptomatic, mostly moderate AS, participating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study was used. ASH was considered present if interventricular septum/posterior wall thickness ratio in end-diastole ≥1...
January 6, 2017: American Journal of Cardiology
keyword
keyword
5673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"